766 related articles for article (PubMed ID: 11992538)
1. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
2. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
3. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.
Bouralexis S; Clayer M; Atkins GJ; Labrinidis A; Hay S; Graves S; Findlay DM; Evdokiou A
Int J Oncol; 2004 May; 24(5):1263-70. PubMed ID: 15067350
[TBL] [Abstract][Full Text] [Related]
5. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis.
Atkins GJ; Bouralexis S; Evdokiou A; Hay S; Labrinidis A; Zannettino AC; Haynes DR; Findlay DM
Bone; 2002 Oct; 31(4):448-56. PubMed ID: 12398939
[TBL] [Abstract][Full Text] [Related]
6. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
[TBL] [Abstract][Full Text] [Related]
7. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P
Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
11. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
12. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
13. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells.
Van Valen F; Fulda S; Schäfer KL; Truckenbrod B; Hotfilder M; Poremba C; Debatin KM; Winkelmann W
Int J Cancer; 2003 Dec; 107(6):929-40. PubMed ID: 14601052
[TBL] [Abstract][Full Text] [Related]
14. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
[TBL] [Abstract][Full Text] [Related]
16. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Petak I; Douglas L; Tillman DM; Vernes R; Houghton JA
Clin Cancer Res; 2000 Oct; 6(10):4119-27. PubMed ID: 11051265
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
18. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA
J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771
[TBL] [Abstract][Full Text] [Related]
20. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
